Collaboration aims to grow clinical evidence supporting the use of bio-Rad’s ddPCR™ technology for molecular residual disease monitoring of patients across a range of solid tumor types.

Sterilis Solutions and Polycarbin proudly announce their strategic partnership aimed at enhancing sustainability in laboratory waste management.

First commercial source of on-demand GMP CD34+ hematopoietic stem cells for clinical manufacturing in the industry. OrganaBio leveraging years of in-house tissue sourcing and cell isolation experience to produce high-quality GMP-compliant cells.

HORIBA Instruments Inc., is proud to announce the launch of their dedicated product solutions to address the impacts of microplastics on the environment and life forms.

Revolutionary genomic research applied an innovative use of multiomics and biomimetic digital twins to unveil new DNA variants associated with the development of endometrial related disorders.

The UK’s Medical Research Council is funding a 10-patient Phase I study to deliver rapid personalised treatment for lung cancer patients.

As of March 2024, the FDA has approved three CD20 × CD3 BsAbs: mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma (R/R FL), glofitamab (Columvi) for relapsed or refractory diffuse B cell lymphoma

Sebastian Arevalo's appointment strategically positions RedShiftBio to capitalize on growing opportunities in the biophysical characterization and bioprocess analytics markets, leveraging a proven track record in driving sales growth.

Highly sensitive and multiplexed assay for the detection, discrimination, and quantification of key mutations in ESR1 gene for breast cancer, developed for bio-Rad’s QX600™ droplet digital™ PCR system.

Applied Biosystems TaqMan QSY2 probes enable multiplexing of research assays for up to 6 targets in a single qPCR reaction with industry-leading TaqMan performance.